Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
20.57
+0.42 (2.08%)
Feb 6, 2026, 12:47 PM EST - Market open
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts that cover Syndax Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $80.23, which forecasts a 290.03% increase in the stock price over the next year. The lowest target is $17 and the highest is $600.
Price Target: $80.23 (+290.03%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 8 | 9 | 8 | 8 | 8 |
| Buy | 2 | 1 | 1 | 3 | 3 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 10 | 11 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $410 → $600 | Buy | Maintains | $410 → $600 | +2,816.87% | Jan 27, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $56 | Strong Buy | Reiterates | $56 | +172.24% | Dec 9, 2025 |
| Barclays | Barclays | Buy Maintains $22 → $35 | Buy | Maintains | $22 → $35 | +70.15% | Nov 24, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $40 → $33 | Buy | Maintains | $40 → $33 | +60.43% | Nov 12, 2025 |
| UBS | UBS | Strong Buy Maintains $35 → $38 | Strong Buy | Maintains | $35 → $38 | +84.74% | Nov 4, 2025 |
Financial Forecast
Revenue This Year
169.88M
from 23.68M
Increased by 617.40%
Revenue Next Year
366.43M
from 169.88M
Increased by 115.70%
EPS This Year
-3.19
from -3.72
EPS Next Year
-1.60
from -3.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 190.2M | 475.6M | ||||
| Avg | 169.9M | 366.4M | ||||
| Low | 155.9M | 231.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 703.0% | 179.9% | ||||
| Avg | 617.4% | 115.7% | ||||
| Low | 558.4% | 36.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.78 | -0.55 | ||||
| Avg | -3.19 | -1.60 | ||||
| Low | -3.35 | -2.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.